NCT00001996已完成2 期
A Phase II Open Randomized Comparison of 566C80 and Pentamidine Isethionate for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients Who Are Intolerant of Trimethoprim / Sulfamethoxazole
Glaxo Wellcome20 个研究点 分布在 1 个国家开始时间: 2001年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 试验地点
- 20
研究概览
简要总结
To compare the safety of atovaquone (566C80) with intravenous (IV) pentamidine for the treatment of mild to moderate Pneumocystis carinii pneumonia (PCP) in AIDS patients who are intolerant of therapy with trimethoprim / sulfamethoxazole (TMP / SMX) by comparing the incidence of premature discontinuation of therapy due to toxicity. To compare the efficacy of 566C80 with intravenous (IV) pentamidine for the treatment of mild to moderate PCP in the same population.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 13 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have the following:
- •History of, or are currently experiencing, intolerance to TMP / SMX, or to another sulfonamide, which required discontinuation of therapy.
- •Pneumocystis carinii pneumonia (PCP).
- •Willing and able to give informed consent.
排除标准
- •Co-existing Condition:
- •Patients with the following conditions or symptoms are excluded.
- •Malabsorption disorder or vomiting that would, in the judgement of the investigator, potentially limit the retention and absorption of an oral therapy.
- •Concurrent bacterial, fungal, or viral pneumonitis, pulmonary Kaposi's sarcoma, or other concurrent illness, or chronic pulmonary disease that, in the investigator's opinion, would make interpretation of drug efficacy difficult.
- •Present occurrences of abnormal prolongation of QT interval on standard, 12 lead EKG.
- •Concurrent Medication:
- •Drugs with potential anti-pneumocystis effect (eg:
- •sulfonamides, dapsone, trimethoprim, other dihydrofolate reductase (DHFR) inhibitors, primaquine, clindamycin, sulfonylureas).
- •Ganciclovir.
- •Zidovudine.
- •Investigational agents including anti-retroviral agents (ddI, ddC, etc.). Patients receiving these drugs prior to entry must discontinue their use during the therapy phase (21 days) of the trial.
- •Corticosteroids (except replacement therapy) during the 21 day treatment period (Strata A and C Patients).
- •Class 1A antiarrhythmics (ie:
- •quinidine, procainamide, disopyramide).
- •Patients with the following are excluded:
- •Judged by the investigator to be in impending respiratory failure.
- •Known intolerance to parenteral pentamidine isethionate, or therapeutic failure with same for treatment of current episode of PCP.
- •Significant psychosis or emotional disorder that, in the investigator's opinion, would preclude the patient from adhering to the protocol.
- •Inability or unwillingness to take medication orally or with food.
- •Prior documented glucose-6-phosphate dehydrogenase (G6PD) deficiency.
- •History, or present occurrences, of abnormal prolongation of QT interval on standard, 12 lead EKG.
- •Termination from FDA 053A due to toxicity.
- •For patients entering under historic intolerance criteria (Groups A and B), prior therapy for this episode of PCP is an exclusion.
- •Prior Medication:
- •Treatment within 4 weeks of entry for a prior episode of PCP.
- •For patients entering under historic intolerance criteria (Groups A and B), prior therapy for this episode of PCP is an exclusion.
- •Adjuvant prednisone for patient enrolled in Strata B or D.
研究者
研究点 (20)
Loading locations...
相似试验
已完成
2 期
A Randomized, Double-Blind Study of 566C80 Versus Septra (Sulfamethoxazole/Trimethoprim) for the Treatment of Pneumocystis Carinii Pneumonia in AIDS PatientsPneumonia, Pneumocystis CariniiHIV InfectionsNCT00000655National Institute of Allergy and Infectious Diseases (NIAID)300
已完成
2 期
Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic EncephalitisHIV InfectionsToxoplasmosis, CerebralNCT00000794National Institute of Allergy and Infectious Diseases (NIAID)100
已完成
不适用
An Open-Label, Uncontrolled Clinical Trial of Oral 566C80 for the Treatment of Patients With Severe PCP Who Are Intolerant and/or Unresponsive to Therapy With Trimethoprim/Sulfamethoxazole and Parenteral PentamidinePneumonia, Pneumocystis CariniiHIV InfectionsNCT00001990Glaxo Wellcome
Unknown
4 期
The ASAP Study - Therapeutic Efficacy of Atovaquone-proguanil vs. Artesunate-atovaquone-proguanil in CambodiaMalariaNCT02297477Armed Forces Research Institute of Medical Sciences, Thailand205
终止
4 期
Multicenter Study to Compare Intravenous and Oral Acetaminophen for the Treatment of Acute Moderate to Severe PainAcute Pain, PostoperativeNCT02746263Mallinckrodt1